The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Europe Cartilage Repair Market would witness market growth of 8.2% CAGR during the forecast period (2018 – 2024).
If cartilage damage remains untreated, it would lead to knee replacement surgery. Knee osteoarthritis is among the most common diseases, due to factors such as aging and obesity. This further enhances the demand for Cartilage repair surgery as Cartilage tissues ability to repair itself is very limited, as there are no blood vessels, and bleeding is vital in healing. The tissue prevents friction between the bones, by absorbing shock in the joints. When damage is caused in the cartilage, it restricts the regular movement of the knee, causing immense pain. It generally occurs after a traumatic and twisting injury to the knee. Moreover, this growth is further supported by the constant technological advancements in the region.
Based on Modality, the market is segmented into Cell based and Non-Cell based. Based on Treatment type, the market is segmented into Intrinsic Repair Stimulus and Palliative. Based on Application, the market is segmented into Fibrocartilage and Hyaline Cartilage. Based on Site outlook, the market is segmented into Knee Cartilage and Other site outlook. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include B. Braun Melsungen AG, Zimmer Biomet, Johnson and Johnson, Smith & Nephew Plc., Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc., and Anika Therapeutics, Inc.